[Media Releases] LegoChem receives patent for a novel oxazolidinone derivative...(kosdaq disclosure, 19 Aug 2014)

Title:  LegoChem Biosciences receives patent for a novel oxazolidinone derivative…

Publication: Disclosed on Kosdaq

Date: 19 August 2014

URL: link to website (contents in Korean)

Summary

LegoChem Biosciences received a patent in U.S. on Aug. 14, for a novel oxazolidinone derivative and medical composition containing same. (Application No.14/008,702)

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).